RxDoctor Payments Data

Anu Tatambhotla, MD

Internal Medicine · Homosassa, FLNPI 1477619559

Payments from drug & device makers

$1,858in general payments, 2019–2025

Across 104 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$298
  • GSK$281
  • Boehringer Ingelheim$249
  • AstraZeneca$221
  • Novo Nordisk$189
  • Pfizer$143
  • plus $477 from 8 others

What the payments were for

  • Food & beverage$1,83599%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,858 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$345,238
Medicare patients
489
Services billed
5,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$154,288
EliquisApixaban83$108,372
MounjaroTirzepatide58$83,822
OzempicSemaglutide53$67,816
FarxigaDapagliflozin Propanediol39$60,426
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$56,258
TrulicityDulaglutide33$50,893
XareltoRivaroxaban28$39,131
ProliaDenosumab21$36,529
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$27,821
Tresiba Flextouch U-100Insulin Degludec63$25,573
EntrestoSacubitril/Valsartan16$25,505
MyrbetriqMirabegron30$24,703
Repatha SureclickEvolocumab23$17,282
Spiriva RespimatTiotropium Bromide18$14,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$249$168,689129 claims
Lilly USA, LLCMounjaro, Trulicity$89$134,71691 claims
PfizerEliquis$143$108,37283 claims
AstraZenecaFarxiga, Breztri Aerosphere$221$88,24668 claims
GSKTrelegy Ellipta, Breo Ellipta$281$68,13564 claims
Novo NordiskOzempic$189$67,81653 claims
AmgenProlia$298$36,52921 claims
NovartisEntresto$91$25,50516 claims
Astellas Pharma US IncMyrbetriq$25$24,70330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Homosassa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →